Table 1.
Previous clinical trials on vitamin D in MS (summarized in [90]) have not taken into the account the need for a dose adjustment according to the individual response index. Therefore, results were of mixed clinical efficacy. New vitamin D3 supplementation trials in MS should consider different dosing based on the patients response index to this allowing thus allowing a proper assessment of the biological and clinical effects.
| Vitamin D Response Index | Daily Vitamin D3 Supplementation | Immune System Balance Restored | Clinical Effect |
|---|---|---|---|
| High | Standard (1000 IU) | + | Present |
| Mid | Standard (1000 IU) | +/− | Partial |
| Mid | Mid (2000 IU) | + | Present |
| Low | Standard (1000 IU) | − | Absent |
| Low | High (4000 IU) | + | Present |